Product Name | Osimertinib | Mereletinib | AZD-9291 |
---|---|
CAS | 1421373-65-0 |
Formula | C28H33N7O2 |
MW | 499.62 |
Appearance | Off-white powder |
Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
---|---|---|---|---|
250 mg | In-stock | $260.00 | Visible after login | |
1 g | In-stock | $650.00 | Visible after login |
Product Name | Osimertinib | Mereletinib | AZD-9291 |
---|---|
CAS | 1421373-65-0 |
Formula | C28H33N7O2 |
MW | 499.62 |
Appearance | Off-white powder |
Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Osimertinib, also known as AZD-9291 and Mereletinib, is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines. Osimertinib was approved in Nov. 2015 by FDA.
PMID: 24893891 PMCID: PMC4315625 DOI: 10.1158/2159-8290.CD-14-0337
PMID: 29467275 DOI: 10.1158/1535-7163.MCT-17-1033